{"filing":{"accession_number":"0001628280-26-058258","cik":"0001854270","ticker":"SNTI","company_name":"Senti Biosciences Holdings, Inc.","form":"8-K","filing_date":"2026-08-20","report_date":"2026-08-14","primary_document":"snti-20260814.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1854270/000162828026058258/snti-20260814.htm"},"events":[{"id":28891,"run_id":26441,"accession_number":"0001628280-26-058258","anchor_item_number":"1.01","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Senti Holdings, a wholly owned subsidiary, issued and sold $4.0 million in aggregate principal amount of Senior Secured Convertible Notes to Celadon Partners SPV 24 pursuant to a Securities Purchase Agreement dated April 27, 2026, creating a new direct financial obligation.","company_name":"Senti Biosciences Holdings, Inc.","ticker":"SNTI","filing_date":"2026-08-20","form":"8-K","submitted_at":null,"items":[{"id":30970,"accession_number":"0001628280-26-058258","item_number":"1.01","item_title":"Entry Into a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Senti Holdings, a wholly owned subsidiary of the Company, issued and sold $4.0 million in aggregate principal amount of Senior Secured Convertible Notes to Celadon Partners SPV 24 pursuant to a Securities Purchase Agreement dated April 27, 2026. This constitutes creation of a new direct financial obligation through debt issuance, which is a material event affecting the registrant's capital structure and financial position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T20:26:54.757893+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":28892,"run_id":26441,"accession_number":"0001628280-26-058258","anchor_item_number":"2.03","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"An entity affiliated with Celadon would merge with and into Senti Holdings, with contingent value rights worth up to $60 million tied to regulatory and sales milestones for SENTI-202, constituting a material acquisition and change of control transaction.","company_name":"Senti Biosciences Holdings, Inc.","ticker":"SNTI","filing_date":"2026-08-20","form":"8-K","submitted_at":null,"items":[{"id":30971,"accession_number":"0001628280-26-058258","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The filing discloses a potential merger transaction in which \"an entity affiliated with Celadon would merge with and into Senti Holdings,\" coupled with issuance of contingent value rights worth up to $60 million tied to regulatory and sales milestones for SENTI-202. Although Item 2.03 is cited, the substance is a material acquisition/change of control requiring stockholder approval via proxy statement, making this fundamentally an M\u0026A activity disclosure under Item 1.01 standards.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T20:26:54.757893+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30970,"accession_number":"0001628280-26-058258","item_number":"1.01","item_title":"Entry Into a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Senti Holdings, a wholly owned subsidiary of the Company, issued and sold $4.0 million in aggregate principal amount of Senior Secured Convertible Notes to Celadon Partners SPV 24 pursuant to a Securities Purchase Agreement dated April 27, 2026. This constitutes creation of a new direct financial obligation through debt issuance, which is a material event affecting the registrant's capital structure and financial position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T20:26:54.757893+00:00","company_name":"Senti Biosciences Holdings, Inc.","ticker":"SNTI","filing_date":"2026-08-20"},{"id":30971,"accession_number":"0001628280-26-058258","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The filing discloses a potential merger transaction in which \"an entity affiliated with Celadon would merge with and into Senti Holdings,\" coupled with issuance of contingent value rights worth up to $60 million tied to regulatory and sales milestones for SENTI-202. Although Item 2.03 is cited, the substance is a material acquisition/change of control requiring stockholder approval via proxy statement, making this fundamentally an M\u0026A activity disclosure under Item 1.01 standards.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T20:26:54.757893+00:00","company_name":"Senti Biosciences Holdings, Inc.","ticker":"SNTI","filing_date":"2026-08-20"}]}